CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
Everfill Oy has developed Everfill®, a bioengineered product designed to enhance wound healing for diabetic patients. By utilizing human growth factors, it promotes tissue regeneration, potentially reducing the need for amputations and improving patient outcomes.
The combination of ageing populations, sedative lifestyle and unhealthy diet results in increase in such diseases as diabetes.
One of the outcomes of diabetes is the occurrence of very severe and deep leg wounds.
As diabetes distorts the body’s normal tissue regeneration processes, it often results in necrosis and amputations, which are still everyday practice even in developed countries.
Everfill Oy is a university spin-off that has developed Everfill®, a patented allogeneic bioengineered produ…
EVERFILL OY
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
